Back to results

Randomized Phase II Trial of Enasidenib-Based Therapies versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A Myelomatch Sub-Study

Objective

To compare the complete remission (CR) rate of enasidenib + ASTX727 and ASTX727 monotherapy in patients with higher-risk IDH2-mutated MDS using IWG2023 response criteria.

Protocol #

MM1MDS-A01

Trial Phase:

Phase II

Principal Investigator:

Maher, Keri

Cancer Type

Other Hematopoietic

Study Site

Virginia Commonwealth University

Get more detailed information at ClinicalTrials.gov

Enrollment Status 1
Age Group Adult
Protocol Type Treatment
Research Study Team Kristin Lantis, MSN, RN, CCRP
Phone: +1 804-828-2177
Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested

Have a question? We're here to help.

Email us or call us with your request.

Send an Email » (804) 628-6430